Does Rallies show 13F holders for NUVB?

Yes. Rallies tracks hedge fund and 13F ownership data for NUVB, including fund names, share counts, latest tracked quarter, and position changes when available.

Is NUVB research on Rallies investment advice?

No. Rallies provides research, data, and educational context for NUVB. It does not provide personalized investment advice.

NUVB (Nuvation Bio Inc.) Stock Analysis - Hedge Fund Holdings

Nuvation Bio Inc. (NUVB) is a publicly traded Healthcare sector company. As of May 20, 2026, NUVB trades at $4.44 with a market cap of $1.47B and a P/E ratio of -10.73. NUVB moved +6.49% today. Year to date, NUVB is -47.50%; over the trailing twelve months it is +107.83%. Its 52-week range spans $1.54 to $9.75. Analyst consensus is strong buy with an average price target of $13.17. Rallies surfaces NUVB's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns NUVB stock?

Hedge funds tracked by Rallies that own NUVB include Duquesne Family, Redmile Group, Panagora Asset, DME Capital, and Farallon Capital. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Nuvation Bio Inc..

NUVB Key Metrics

Key financial metrics for NUVB
Metric	Value
Price	$4.44
Market Cap	$1.47B
P/E Ratio	-10.73
EPS	$-0.42
Dividend Yield	0.00%
52-Week High	$9.75
52-Week Low	$1.54
Volume	4.47M
Avg Volume	0
Revenue (TTM)	$143.05M
Net Income	$-145.99M
Gross Margin	0.00%

Top Hedge Funds Holding NUVB

Duquesne Family holds 4.54M shares of NUVB, changed +0.00% as of Mar 31, 2026.
Redmile Group holds 3.15M shares of NUVB, changed -0.32% as of Mar 31, 2026.
Panagora Asset holds 341.76K shares of NUVB, changed -43.55% as of Dec 31, 2024.
DME Capital holds 34.99K shares of NUVB, changed +0.00% as of Mar 31, 2026.
Farallon Capital holds 29.00K shares of NUVB, changed +0.00% as of Mar 31, 2026.

Latest NUVB News

Nuvation Bio Completes Thermo Fisher Tech Transfer for IBTROZI Manufacturing — May 13, 2026
Nuvation Bio Logs $18.5M Q1 IBTROZI Revenues, Secures Japan Rights for Safusidenib — May 4, 2026
Analysts Raise Nuvation Bio 2026 Revenue Forecast 15.6%, Q1 Seen at $62.3M — May 1, 2026
Nuvation Bio’s Taletrectinib Recommended in NCCN CNS Guidelines with 76.5% Intracranial Response — Apr 27, 2026
IBTROZI Shows 49.7-Month Duration and 89.8% Response in ROS1+ NSCLC Trials — Apr 21, 2026

Recent NUVB Insider Trades

Wentworth Kerry sold 36.75K (~$184.28K) on Apr 17, 2026.
Liu Dongfang sold 50.00K (~$251.00K) on Apr 17, 2026.
Wentworth Kerry sold 200.00K (~$903.56K) on Apr 6, 2026.

NUVB Analyst Consensus

7 analysts cover NUVB: 0 strong buy, 6 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $13.17.

Common questions about NUVB

Who owns NUVB stock?: Hedge funds tracked by Rallies that own NUVB include Duquesne Family, Redmile Group, Panagora Asset, DME Capital, and Farallon Capital. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Nuvation Bio Inc..
Does Rallies show 13F holders for NUVB?: Yes. Rallies tracks hedge fund and 13F ownership data for NUVB, including fund names, share counts, latest tracked quarter, and position changes when available.
Is NUVB research on Rallies investment advice?: No. Rallies provides research, data, and educational context for NUVB. It does not provide personalized investment advice.